Jupiter Topco LLC acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,236,102 shares of the company's stock, valued at approximately $94,014,000. Jupiter Topco LLC owned about 4.70% of Amylyx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of the business. Landscape Capital Management L.L.C. grew its position in shares of Amylyx Pharmaceuticals by 17.5% in the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company's stock valued at $148,000 after purchasing an additional 1,825 shares in the last quarter. KBC Group NV purchased a new stake in shares of Amylyx Pharmaceuticals during the 1st quarter valued at $26,000. Meeder Asset Management Inc. bought a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter worth $25,000. State of Wyoming bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $40,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Amylyx Pharmaceuticals by 13.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company's stock worth $326,000 after purchasing an additional 3,198 shares in the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In related news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the sale, the insider owned 194,090 shares of the company's stock, valued at $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.90% of the stock is currently owned by company insiders.
Amylyx Pharmaceuticals Trading Down 1.0%
AMLX stock opened at $37.08 on Thursday. The stock has a market capitalization of $4.13 billion, a PE ratio of -25.93 and a beta of -0.21. Amylyx Pharmaceuticals, Inc. has a 12-month low of $8.94 and a 12-month high of $41.14. The stock's 50 day simple moving average is $21.72 and its 200 day simple moving average is $17.20.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages have commented on AMLX. Robert W. Baird increased their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an "outperform" rating in a research report on Wednesday, August 19th. HC Wainwright boosted their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, August 18th. Wall Street Zen downgraded Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $36.25.
Check Out Our Latest Research Report on Amylyx Pharmaceuticals
About Amylyx Pharmaceuticals
(
Free Report)
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
